Sequential afatinib and osimertinib in patients with EGFR mutation-positive non-small-cell lung cancer : updated analysis of the observational GioTag study
© 2019 Maximilian J Hochmair
2019
2020-09-11 14:42:57
1033
non-small cell lung carcinoma - therapy, drug therapy, afatinib, osimertinib, GioTag study
nedrobnocelični karcinom pljuč - terapija, terapija z zdravili, afatinib, osimertinib, raziskava GioTag
Future Medicine Ltd
Maximilian J
Hochmair
70
Alessandro
Morabito
70
Desiree
Hao
70
Cheng-Ta
Yang
70
Ross A
Soo
70
James C-H
Yang
70
Rasim
Gucalp
70
Balazs
Halmos
70
Lara
Wang
70
Angela
Märten
70
Tanja
Čufer
70
UDK
4
616.2
ISSN pri članku
9
1744-8301
DOI
15
10.2217/fon-2019-0346
COBISS_ID
3
2048610929
OceCobissID
13
521824025
RAZ_Hochmair_Maximilian_J_i2019.pdf
1659618
Predstavitvena datoteka
2021-05-14 13:47:29
RAZ_Hochmair_Maximilian_J_i2019.pdf
1158381
Priloga
2021-05-14 13:48:13
0
Izvorni URL
2020-09-11 14:43:03